Chronic treatment with acetaminophen protects against liver aging by targeting inflammation and oxidative stress

Rocío Brea¹,* , Pilar Valdecantos¹,²,* , Patricia Rada¹,²,* , Rosa Alen¹,² , Carmelo García-Monzón³,⁶, Lisardo Boscá¹,⁴, Marina Fuertes-Agudo⁵,⁶, Marta Casado⁵,⁶, Paloma Martín-Sanz¹,⁶,# , Ángela M. Valverde¹,²,#

¹Instituto de Investigaciones Biomédicas “Alberto Sols”, (CSIC-UAM), Department of Metabolism and Cellular Signaling, Madrid 28029, Spain  
²Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem) ISCIII, Madrid 28029, Spain  
³Liver Research Unit, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria Princesa, Madrid 28009, Spain  
⁴Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERcv) ISCIII, Madrid 28029, Spain  
⁵Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia 46010, Spain  
⁶Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) ISCIII, Madrid 28029, Spain  
*Equal contribution  
#Senior authorship

Correspondence to: Ángela M. Valverde, Paloma Martín-Sanz; email: avalverde@iib.uam.es, pmartins@iib.uam.es

Keywords: APAP, aging, inflammation, liver, oxidative stress

Received: September 22, 2020  Accepted: March 2, 2021  Published: March 29, 2021

Copyright: © 2021 Brea et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The liver exhibits a variety of functions that are well-preserved during aging. However, the cellular hallmarks of aging increase the risk of hepatic alterations and development of chronic liver diseases. Acetaminophen (APAP) is a first choice for relieving mild-to-moderate pain. Most of the knowledge about APAP-mediated hepatotoxicity arises from acute overdose studies due to massive oxidative stress and inflammation, but little is known about its effect in age-related liver inflammation after chronic exposure. Our results show that chronic treatment of wild-type mice on the B6D2Jrccc/Hsd genetic background with APAP at an infratherapeutic dose reduces liver alterations during aging without affecting body weight. This intervention attenuates age-induced mild oxidative stress by increasing HO-1, MnSOD and NQO1 protein levels and reducing ERK1/2 and p38 MAPK phosphorylation. More importantly, APAP treatment counteracts the increase in Cd8⁺ and the reduction in Cd4⁺ T lymphocytes observed in the liver with age. This response was also found in peripheral blood mononuclear cells. In conclusion, chronic infratherapeutic APAP treatment protects mice from age-related liver alterations by attenuating oxidative stress and inflammation.

INTRODUCTION

The liver is a pivotal organ with an extensive variety of functions, including drug metabolism and detoxification, protein synthesis, and regulation of energy metabolism, among others [1]. Most liver functions appear to be well preserved with age, but some changes in liver morphology and physiology,
such as enhanced hepatocyte size, increased number of binucleated cells, and reduction in mitochondrial number [2], have been associated with increased risk of hepatic injury and development of many chronic liver diseases [3]. Inflammation is of particular interest, since aging is characterized by increased levels of a number of pro-inflammatory molecules including acute phase proteins (CRP and serum amyloid A), cytokines (TNF-α, IL-6, and IL-8), and adhesion molecules (sICAM-1 and sVCAM-1) in circulation, a phenomenon that has been termed "inflammaging" [4–7]. It is also hypothesized that failure of anti-inflammatory and inflammation resolving mechanisms contributes to chronic inflammation in the elderly. In this context, aging is associated with substantial changes in both innate and adaptive immune systems in order to counteract functional defects of Cd8+ T lymphocytes [8, 9] and the decrease in the function of Cd4+ T helper cells [10]. Moreover, recent advances point to natural killer (NK) and natural killer T (NKT) cells as a bridge between the innate and adaptive immune systems [11]. Particularly, the role of the liver as a reservoir of pluripotent stem cells, which give rise to multiple cell lineages, including NKT [12, 13] and Cd8+ T cells [14], and the adaptive immune response during chronic non-alcoholic fatty liver disease (NAFLD) has been the focus of recent research as reviewed [15]. Thus, slow or reverse the process of inflamming is highly relevant to achieve a healthy aging and improve well-being.

According to many international guideline recommendations, acetaminophen (N-acetyl-p-aminophenol, paracetamol, APAP) is a first choice drug for relieving mild-to-moderate pain based on its analgesic and antipyretic effects [16]. At therapeutic doses (up to 4 g per day in adult humans), APAP represents a valuable agent in the pharmacological management of pain, especially for patients who cannot tolerate non-steroid anti-inflammatory drugs such as aspirin, ibuprofen or salicylates, which can cause detrimental effects on the gastrointestinal tract and kidney [17]. At non-toxic doses, APAP is rapidly metabolized in the liver through glucuronidation and sulfation. However, a small part is also oxidized by cytochrome P450 isofoms (mainly CYP2E1, CYP3A4, and CYP1A2) generating the toxic metabolite N-acetyl-p-amino benzoquinone imine (NAPQI). This intermediate is highly reactive and cytotoxic. At therapeutic doses, NAPQI is detoxified by glutathione (GSH) and eliminated in urine or bile as APAP-cysteine, APAP-N-acetyl cysteine, and APAP-GSH. On the contrary, after an overdose glucuronidation and sulfation pathways become saturated triggering a rapid depletion of the hepatic GSH pool. As a result, massive amounts of NAPQI bind to the cysteine groups of proteins and generate APAP-protein adducts leading to oxidative stress and inflammation [17].

Hitherto, most of the knowledge about APAP-mediated hepatotoxicity arises from studies describing its toxic effect upon APAP overdose in experimental mouse models or humans [18–20]. Our recent data revealed that sirtuin 1 (SIRT1) overexpression confers protection against acute APAP-mediated hepatotoxicity by targeting IL1β/NF-κB-mediated inflammation [21]. However, little is known about the effect of APAP after a chronic or infratherapeutic exposure in age-related liver inflammation.

Taking these into account, the present study aims to investigate in detail the effects of chronic treatment of mice with an infratherapeutic dose of APAP and its relationship with age-related oxidative stress and inflammation in the liver.

**RESULTS**

An infratherapeutic dose of APAP has a mild beneficial effect in hepatic parameters altered during aging without affecting body weight

To investigate the effects of chronic APAP treatment and its relationship with aging-mediated deleterious effects in the liver, mice were treated with an infratherapeutic dose of APAP dissolved in the drinking water for 8 months as detailed in “Methods” section. We used wild-type mice on the B6D2JRcc/Hsd genetic background as we previously demonstrated that they are susceptible to diet-induced metabolic and liver damage [22, 23]. APAP treatment did not induce any abnormal clinical signs during the study. As shown in Figure 1A, the mean daily water consumption did not significantly differ between groups regardless of APAP supplementation. Furthermore, APAP treatment did not result in any significant change in the group mean body weight and mean cumulative net body weight gain when compared to the untreated control group (Figure 1B). In order to not only analyze the impact of APAP, but also the effect of age, a cohort of two-month-old mice (2 m/o) was included. As expected, total body and liver weight observed in 14 m/o mice was significantly higher than that of the 2 m/o group and also liver-to-body weight ratio was reduced (Figure 1C). However, APAP treatment did not alter the changes associated with age.

To assess the impact of in vivo chronic APAP exposure on glucose homeostasis, GTT was performed in all groups at the end of the treatment. As shown in Supplementary Figure 1A, 1B, no significant differences were found in glucose tolerance regardless
of aging or APAP treatment. To study the specific effect of APAP treatment in the liver, PTT was conducted (Supplementary Figure 1C, 1D) and, in the same line, we did not find differences among experimental groups although a non-significant delayed response was observed in mice receiving APAP. Thus, our results demonstrated that in these cohorts of mice neither age nor APAP treatment impaired whole-body glucose homeostasis.

Next we addressed whether chronic treatment with an infratherapeutic dose of APAP induces liver alterations. To analyze histological damage, liver sections were stained with H&E and evaluated by a hepatopathologist. As shown in Figure 2A, 2B, both steatosis and inflammation induced by aging were significantly attenuated by the treatment with APAP. Consequently, a reduced NAS score was observed in 14 m/o + APAP group. The results obtained after staining liver sections with Oil Red O (Figure 2C) agree with these data, showing less lipid accumulation in APAP-treated 14 m/o mice when compared to the 14 m/o group. In addition, evidence of aging-associated liver changes was detected in 14 m/o mice as reflected by the analysis of plasma transaminases (ALT, AST) (Figure 2D) that showed a moderate increase in agreement with other

Figure 1. Chronic APAP treatment at an infratherapeutic dose does not change body and liver weight. (A) Mean daily water consumption. (B) Body weight of mice throughout 8 months of APAP treatment. (C) Comparison of the body weight, liver weight and liver-to-body weight ratio of 2 m/o, 14 m/o and 14 m/o + APAP mice. Data are represented as the mean ± S.E.M. (n = 17-21 mice per group). Statistical analysis was performed by Mann-Whitney test (A), ANOVA test for repeated-measures (B) and Kruskal-Wallis or Brown-Forsythe and Welch ANOVA test followed by their respective post-hoc test (C). ** P < 0.01 and *** P < 0.001 vs. 2 m/o; ns vs. 14 m/o.
Figure 2. Chronic APAP exposure ameliorates the effect of age in liver alterations. (A, C) Representative images (10X and 20X) of H&E (A) and Oil Red O (C) staining performed on various sections of livers from 2 m/o, 14 m/o and 14 m/o + APAP mice. (B) Steatosis NAS score, inflammation NAS score, and total NAS score. (D) Plasma ALT, AST and LDH levels from 2 m/o, 14 m/o and 14 m/o + APAP mice. Values are expressed in international units per liter (U/L). Data are represented as the mean ± S.E.M. (n = 6-18 mice per group). Statistical analysis was performed by one-way ANOVA or Brown-Forsythe and Welch ANOVA test followed by their respective post-hoc test. * P < 0.05, ** P < 0.01 and *** P < 0.001 vs. 2 m/o; # P < 0.05 and ## P < 0.01 vs. 14 m/o.
More importantly, in APAP-treated mice, plasma ALT, AST and lactate dehydrogenase (LDH) levels were similar to those of 2 m/o (Figure 2D) indicating that chronic APAP exposure ameliorates age-related liver dysfunction.

Chronic APAP administration attenuates age-induced mild oxidative stress in mice

It is classically argued that oxidative stress may be one of the causal factors underlying the aging process due to a reduction of the antioxidant defenses [26]. Since long-term APAP administration ameliorates age-associated liver changes, we next explored the antioxidant signature in the liver. Results depicted in Figure 3A revealed that protein levels of two-well known antioxidant enzymes, HO-1 and MnSOD, were reduced with age whereas an unexpected increase in NQO1 was found. Importantly, APAP treatment reinforced the antioxidant response of the liver by increasing HO-1, MnSOD and NQO1 protein levels. In agreement with these data, APAP also promoted a slight increase in mRNA levels of Nfe2l2 (encoding NRF2) and its target genes Hmox1 and Sod2 (Figure 3B). In contrast to the protein levels, Nqo1 mRNA levels did not show differences after 8-months APAP treatment. Also, no differences were found in nuclear NRF2 protein levels (Supplementary Figure 2). Furthermore, the antioxidant status was evaluated by measuring lipid peroxidation (LPO) and cellular O$_2^-$ content in the liver. As shown in Figure 3C, APAP treatment attenuated age-induced LPO levels. Also, DHE-derived fluorescence analyzed in liver sections revealed that whereas aging increased O$_2^-$ production, treatment with an infratherapeutic dose of APAP significantly reduced O$_2^-$ content (Figure 3D). Altogether, our results strongly suggest that chronic APAP administration at an infratherapeutic dose in mice favored the preservation of an appropriate antioxidant/oxidant balance in the liver, thereby maintaining healthy hepatic aging.

To date, it is well-recognized that MAPKs are activated in response to cell stressors such as oxidative and inflammatory triggers and have been implicated in different modes of hepatocyte death [27]. Indeed, numerous studies have proven the contribution of JNK, p38 MAPK, and ERK1/2 during acute APAP-induced liver toxicity [27–29]. However, little is known about their contribution after chronic exposure to infratherapeutic doses of this drug. As shown in Figure 3E, an increase in p38 MAPK and ERK1/2 phosphorylation levels was observed with age. Moreover, in mice receiving chronic APAP administration, a decrease in the phosphorylation of both kinases was found; being differences in pERK1/2 levels statistically significant, and suggesting a protective anti-aging effect of this drug. Likewise, under these conditions we were unable to detect changes in the phosphorylation of JNK1/2 in livers from 2 m/o or 14 m/o mice regardless of the APAP treatment (data not shown).

Previous results showed that after an APAP overdose activation of NF-κB-mediated signaling triggers oxidative stress and a pro-inflammatory response, ultimately causing liver damage [21, 30, 31]. To determine whether NF-κB signaling is modulated in the liver by chronic and infratherapeutic APAP administration, nuclear p65-NF-κB and cytosolic IκBα protein levels were analyzed. As shown in Supplementary Figure 2, no significant changes were found regardless of aging or treatment, ruling out the involvement of the NF-κB pathway in the liver neither in aging nor in the protective effect mediated by chronic APAP administration.

Impact of aging and chronic treatment with APAP in the immune signature of the liver

Since aging is associated with changes in the balance of Cd8$^+$ and Cd4$^+$ T lymphocyte populations, we evaluated the impact of the chronic treatment with an infratherapeutic dose of APAP in the immune signature of the liver by isolating several populations of non-parenchymal cells (NPCs) followed by flow cytometry analysis. As depicted in Figure 4A, Cd8$^+$ T cells were increased in livers from 14 m/o mice in parallel with a reduction in Cd4$^+$ T cells. Importantly, both effects were completely prevented by APAP treatment. The decrease in Cd8$^+$ T cells in 14 m/o mice receiving APAP was also assessed by immunofluorescence of liver sections (Supplementary Figure 3).

As reported by Taniguchi and co-workers [11], the NKT system plays a key role in adaptive and innate immune responses. Moreover, the role of the liver as reservoir of NKT cells has been described [12, 13]. Taking this into account, the analysis of Cd8$^+$ and Cd4$^+$ populations gated from NKT$^+$ cells revealed similar pattern than that of Cd3$^+$ lymphocytes (Figure 4B). According with these results, we also found a decrease in Arg1 (encoding Arginase 1), Clec10a (encoding MGL1) and Ccl2 (encoding MCP1) mRNA levels, all markers of the M2 anti-inflammatory response, in 14 m/o mice that were reversed by APAP treatment (Figure 5A). Recently, Haas and co-workers have defined circulating Cd8$^+$ T cells as good predictors of NAFLD progression [14]. Interestingly, our results showed a positive correlation between levels of transaminases and the amount of Cd8$^+$ cells from both Cd3$^+$ and NKT populations (Figure 5B). Moreover, we observed an increase in resident recruited monocytes (Cd11b$^+$Ccr2$^+$Ly6c$^-$) in 14 m/o livers which was
Figure 3. Chronic APAP administration at an infratherapeutic dose increases Nrf2-targets HO-1, NQO1 and MnSOD and enhanced antioxidant capacity. (A) Representative Western blots showing HO-1, MnSOD and NQO1 protein levels in liver extracts from 2 m/o, 14 m/o and 14 m/o + APAP mice. GAPDH and VINCULIN levels were used as loading controls (n = 6-14 mice per group) (see original western blot in Supplementary Figure 6). (B) Liver mRNA expression of Nfe2l2, Hmox1, Sod2 and Nqo1 from 2 m/o, 14 m/o and 14 m/o + APAP mice, analyzed by qRT-PCR. Values have been normalized against Hprt1 mRNA, and expressed as fold of change vs. 2 m/o (n = 6-8 mice per group). (C) Hepatic LPO levels of 2 m/o, 14 m/o and 14 m/o + APAP mice (n = 6-8 mice per group). (D) Detection of O$_2^•$− in frozen liver sections from 2 m/o, 14 m/o and 14 m/o + APAP group mice using DHE (n = 5 mice per group). (E) Representative Western blots showing phospho-ERK1/2 and phospho-p38 MAPK protein levels. Total ERK1/2 and p38 MAPK levels were used as loading controls, respectively (n = 9-14 mice per group) (see original western blot in Supplementary Figure 7). For (A, E), graphs depict densitometric quantifications of the indicated protein levels. Data are represented as the mean ± S.E.M. Statistical analysis was performed by Kruskal-Wallis, one-way ANOVA or Brown-Forsythe and Welch ANOVA test followed by their respective post-hoc test. * P < 0.05 and *** P < 0.001 vs. 2 m/o; # P < 0.05 and ### P < 0.001 vs. 14 m/o.
Figure 4. Analysis of lymphoid populations in liver NPCs from 2 m/o, 14 m/o and 14 m/o + APAP mice by flow cytometry. (A) Percentage of Cd8+ (left) and Cd4+ (right) from Cd45+Cd3+ cells and representative images of flow cytometry analysis. (B) Percentage of Cd8+ (left) and Cd4+ (right) from Cd45+Cd3+NK1.1+ cells and representative images of flow cytometry analysis. Data are represented as the mean ± S.E.M. (n = 14-16 mice per group). Statistical analysis was performed by Brown-Forsythe and Welch ANOVA test followed by their respective post-hoc test. * P < 0.05, ** P < 0.01 and *** P < 0.001 vs. 2 m/o; * P < 0.05 and ## P < 0.01 vs. 14 m/o.
reversed by APAP (Supplementary Figure 4A), without changes in other inflammatory cell populations (Supplementary Figure 4B–4E). Immunostaining revealed that the total population of monocytes positive for Ly6c increased in the liver during aging in either untreated or APAP-treated mice also confirmed by flow cytometry (Supplementary Figure 4F). These results suggest that the balance between Cd4/Cd8 T lymphocyte populations plays a more relevant role in the APAP-mediated protective effect rather than monocyte inflammatory cells.

The absence of validated circulating biomarkers for the evolution of chronic liver diseases is one of the main problems that limit the correct diagnosis of these pathologies. In this context, we analyzed the inflammatory responses in PBMCs of the experimental groups of mice by flow cytometry. In agreement with the data from NPCs, we did not find changes in macrophages and total lymphocytes in PBMCs neither by age or treatment (Supplementary Figure 5A, 5C). Although in NPCs the neutrophils population did not change between groups (Supplementary Figure 4D), in PBMCs this population was increased in 14 m/o mice in comparison with 2 m/o young mice and this effect was not observed in the 14 m/o + APAP group (Supplementary Figure 5B). Importantly, we found a similar pattern in the changes of Cd8+ and Cd4+ T populations (from Cd3+) in NPCs and PBMCs (Figure 6A, 6C) and, interestingly, they were positively

![Image](54x151 to 558x536)

**Figure 5.** Analysis of markers of the M2 anti-inflammatory response and correlation of Cd8+ T cells with ALT. (A) mRNA expression of Arg1, Clec10a and Ccl2 in livers from 2 m/o, 14 m/o and 14 m/o + APAP mice, analyzed by q-PCR. Values were normalized against Hprt1 mRNA and expressed as fold of change vs. 2 m/o. (B) Linear regression between plasma ALT activity levels and the 2 populations of Cd8+ T cells from 2 m/o, 14 m/o, and 14 m/o + APAP mice. Data are expressed as the mean ± S.E.M. (n = 6-16 (A), 9-12 (B) mice per group). Statistical analysis was performed by Kruskal-Wallis or one-way ANOVA test followed by their respective post-hoc test. ** P < 0.01 and *** P < 0.001 vs. 2 m/o; + P < 0.05 and ## P < 0.01 vs. 14 m/o.

www.aging-us.com 7807 AGING
correlated (Figure 6B). These results were also confirmed in Cd8\(^+\) and Cd4\(^+\) gated from NKT cells of PBMCs (Figure 7A, 7B).

To corroborate the role of circulating Cd8\(^+\) cells as a potential biomarker of liver disease we analyzed the correlation of this population with the NAS score in our experimental model. The results shown in Figure 6D confirmed a significant positive regression between Cd8\(^+\) T cells (from Cd3\(^+\)) and the NAS score. Moreover, Cd4\(^+\) cells (from Cd3\(^+\) and also Cd3\(^+\)NK1.1\(^+\)) were inversely correlated with the NAS score (Figures 6D, 7C).

**DISCUSSION**

To date, age-related changes in the metabolism after APAP exposure are poorly understood. In fact, very few studies have investigated the effect of chronic treatment with APAP in hepatotoxicity, since most of the work...
has been focused in identifying the molecular mechanisms responsible of fulminant liver failure upon APAP intoxication [32–34]. Herein, the objective of this study was to evaluate the impact of chronic APAP administration in middle-aged mice in metabolic-related parameters with a major focus in the inflammatory responses of the liver. For this purpose, we administered the infratherapeutic APAP dose of 57.1 g/kg/day added to the drinking water to mice during 8 months since our previous study showed APAP-protein adducts, but not hepatotoxicity in this intervention [35]. The starting time-period (6 months of age) of APAP administration was chosen to delineate a stage of middle age, time at which metabolic risks arise [36, 37].

To date, it is recognized that the genetic background of the preclinical animal models can impact on their metabolic phenotype [38–40]. In our previous studies [35, 41] mice on the C57BL/6J x 129Sv/J (B6;129Sv) genetic background were investigated at different ages, while mice on B6D2JRcc/Hsd genetic background, highly susceptible to diet-induced metabolic and liver damage [22, 23], were used in the present study. In fact, differences in body weight among the two genotypes became more evident with age indicating a background-specific susceptibility to weight-related metabolic alterations through aging. These results suggest that APAP chronically administered in a more obesogenic background could mask its effects on metabolic alterations. However, differences in APAP metabolism including expression levels of CYP2E1 or induction of protective factors such as FGF15/19 [42, 43] could also account for these differences.

Specific age-related changes in the liver have been previously reported including increased hepatocyte size, binucleated cells, augmented lobular inflammation, and reduction in mitochondrial number [2, 44]. Overall, these changes may significantly affect liver morphology, physiology and oxidative capacity. Herein we show that whereas aging led to a significant increase in steatosis and inflammation in the liver, it only modestly elevated transaminases and LDH, pointing to mild alterations. From a therapeutic perspective, reversion or prevention of age-related liver damage might improve health and lifespan in the elderly [45, 46]. In this regard, the above-mentioned age-related effects in the liver were prevented by chronic treatment of B6D2JRcc/Hsd mice with an infratherapeutic dose of APAP, suggesting a protective effect of this intervention independently of body weight gain or glucose metabolism.

Oxidative stress may be one of the causal factors underlying metabolic dysfunction during aging due to a decline of the antioxidant defenses [26, 47–49]. Accordingly, our results illustrated reduced HO-1 and MnSOD protein levels in 14 m/o mice. Also, in line with previous studies [50–52], those mice showed an increase in NQO1 protein and Nqo1 mRNA suggesting a protective mechanism to counteract the aging process. By contrast, other studies reported increased levels of HO-1 in the liver during aging [53, 54].

![Figure 7](https://aging-us.com/)

**Figure 7.** Analysis of NKT subpopulations in PBMCs from 2 m/o, 14 m/o and 14 m/o + APAP mice by flow cytometry. (A) Percentage of Cd8+ cells from Cd45+Cd3+NK1.1+ cells. (B) Percentage of Cd4+ cells from Cd45+Cd3+NK1.1+ cells. (C) Linear regression between NAS score and Cd4+ cells from Cd45+Cd3+NK1.1+ cells in PBMCs. Data are represented as the mean ± S.E.M. (n = 9-14 mice per group). Statistical analysis was performed by Brown-Forsythe and Welch ANOVA test followed by their respective post-hoc test. * P < 0.05 and ** P < 0.01 vs. 2 m/o; # P < 0.01 and ### P < 0.001 vs. 14 m/o.
effect of this intervention. Notably, HO-1 was also found elevated in rat livers between 12 and 36 h after exposure to an APAP overdose [55, 56] and, in this line, HO-1 induction is well recognized as a cytoprotective response against liver injury by suppressing oxidative stress and inflammation [57, 58]. Also, reduction of MnSOD activity aggravates APAP-induced liver injury and mitochondrial toxicity in mice [59, 60]. On the other hand, Moffit et al. reported that after an APAP overdose NQO1 enzymatically reduces NAPQI to be converted in APAP, partially decreasing the deleterious effect of this reactive metabolite [61]. Likewise, Mach et al. demonstrated that old rats acutely treated with an APAP overdose were more protected against hepatotoxicity than young animals due to reduced formation of NAPQI [51]. Taking this into account, we hypothesize that age-related increased NQO1 likely contributes to the protective effect of APAP, since both aging and APAP cooperated in preventing the accumulation of NAPQI. Of note, our results did not show translocation of NRF2 to the nucleus either with age or APAP, suggesting that alternative mechanisms are required to upregulate the antioxidant enzymes. In fact, HO-1, NQO1 and MnSOD expression is also regulated by NRF2-independent mechanisms [62–64]. Importantly, we also evidenced that age-induced LPO and DHE-derived fluorescence are counteracted after chronic APAP treatment, an effect likely mediated by these antioxidant enzymes. It is important to highlight that mild oxidative stress has been proposed as a positive hormetic event since low protein and lipid oxidative damage may have prophylactic effects over several diseases associated to aging [65]. In this context, “hormesis” is defined as a process in which exposure to a low dose of a chemical agent or environmental factor that is damaging at higher doses induces an adaptive beneficial effect on the cell or organism [66, 67]. Therefore, the chronic infratherapeutic APAP treatment performed in our study could be an anti-aging hormetic mechanism by promoting adaptive biological responses to counteract deleterious liver alterations induced by aging.

Previous publications pointed ROS or aging-induced activation of MAPK family proteins in various tissues including brain, lung, muscle, and liver [68–70]. Thus, MAPK signaling might be increased as indicative of chronic stress through life, even in the absence of a toxic challenge. In this regard, phosphorylation levels of ERK1/2 and p38 MAPK were significantly increased in livers from 14 m/o mice, an effect markedly attenuated to levels found in young mice after chronic treatment with APAP at an infratherapeutic dosage in parallel with a reduction in ROS levels. Thus, targeting ERK1/2 and p38 MAPK activities may be crucial in delaying age-related liver alterations.

During aging, adaptive immunity declines, whereas innate immunity seems to be activated which induces a characteristic proinflammatory profile regulated by NF-κB [71]. Contrary to our findings after an acute toxic APAP exposure [21], activation of the NF-κB signaling pathway was not detected upon chronic exposure to infratherapeutic doses of the drug. These results are consistent with the fact that APAP at this infratherapeutic dosage does not cause liver damage, but rather favors a protective effect.

Previous studies have shown that NPCs play a role in physiological liver functions as well as in acute liver damage, such as drug-induced liver injury (DILI), hepatitis, as well as in acute inflammation, and in chronic liver diseases, such as liver fibrosis and cirrhosis [72]. In this regard and due to the difficulties in evaluating inflammatory processes in the whole liver, we analyzed in detail the NPCs populations by flow cytometry. It is well-known that aging is associated with immunosenescence, a complex immune remodeling process that affects particularly Cd3⁻Cd8⁺ T cells [73]. In agreement, Cd3⁻Cd8⁺ T population increased in livers from 14 m/o mice revealing for the first time liver-specific age-dependent immunomarkers with a similar profile recently found in mice with NAFLD [14, 74]. In fact, in livers from 14 m/o mice both steatosis and inflammation NAS scores resemble those of mice with fatty liver reported by our group [75, 76]. More importantly, a recent study in humans with different stages of NAFLD revealed a linear correlation between steatosis, inflammation and global NAS scores with hepatic Cd8⁺ T cells [14], also in agreement with our data. Notably, this increase in Cd8⁺ T cells found in human livers with NAFLD was more evident in non-diabetic patients, also coincident with the absence of alterations in systemic glucose homeostasis in our mice model. It is noteworthy to mention that the decrease of Cd3⁻Cd4⁺ T cells is also an immune signature of 14 m/o mice that correlates with increased LPO and DHE staining together with a drop of antioxidant defenses (i.e. HO-1 and MnSOD). Again, our results are in agreement with data reported by Ma et al. in a mouse model of NAFLD showing a reduction of the Cd3⁻Cd4⁺ population as a result of the dysregulation of lipid metabolism and the increase in mitochondrial ROS [77]. Regarding Cd3⁻NK1.1⁻Cd8⁺ population, the increase found in livers from 14 m/o mice agrees with the pattern previously described by our group [78] and others [79] in mice with non-alcoholic steatohepatitis (NASH) and also in human NASH patients [80]. Besides NAFLD, to the best of our knowledge the increase in this circulating cell population with aging has been reported, but not in the liver, highlighting the relevance of our findings regarding the immune signature of the liver throughout age. Finally, we found higher recruited myeloid cells
(Cd11b+Ccr2+Ly6c+) in 14 m/o mice livers as also reported in obese mice [81]. Importantly, our data revealed that chronic treatment with APAP at an infratherapeutic dose protects against the imbalance in liver immune NPCs thorough life. These data were corroborated by increased Arg1 and Ccl2 mRNA levels, a readout of M2 stage. The benefit of this chronic treatment on liver inflammation might be explained by the above mentioned effect of APAP in enhancing antioxidant defenses, thereby limiting hepatic inflammation. In fact, as discussed above, the drop of Cd3+Cd4+ T cells during NAFLD was attributed to mitochondrial ROS [77]. Thus, it is reasonable to suggest that this also occurs in the liver during aging. Similar direct relationship (oxidative stress and inflammation) can be extended to the elevations of cytotoxic lymphocytes and NKTs found in 14 m/o mice that did not receive APAP and manifested increased LPO and DHE staining. More interestingly, Cd8+ T cells of the liver, including both total and the specific NK1.1+Cd3+ population, correlated with transaminase levels, pointing to this population as an indicative of liver inflammatory damage with potential diagnostic value. Thus, this experimental approach is likely valuable as predictor of unhealthy liver through life, particularly in middle age individuals at risk to develop metabolic disturbances.

Due to the limitations in obtaining liver samples for diagnostic purposes, and based on the study of Haas et al. correlating blood Cd8+ T lymphocytes with the NAS score in NASH patients [14], we analyzed Cd8+ and Cd4+ lymphocytes in PBMCs and found similar profile than hepatic NPCs in all experimental groups. Of relevance, these inflammatory populations in PBMCs linearly correlated with the NAS score of the mice. Moreover, hepatic and blood lymphocytes correlated with a broad range of NAS score, pointing to PBMCs as potential biomarkers for diagnosis and monitoring age-associated hepatic chronic inflammation frequently associated to metabolic diseases.

Collectively, our data suggest that chronic administration of an infratherapeutic dose of APAP exerts hepatic protection against liver alterations during aging by maintaining the balance of the redox status and preventing immunosenescence that ultimately favors healthy aging. We also described a correlation between liver damage and an immune signature in liver and PBMCs pointing PBMCs as potential biomarkers of liver alterations during aging.

MATERIALS AND METHODS

Chemicals

The antibodies were obtained from Merck-Sigma Aldrich (St. Louis, MO, USA), Cell Signaling Technology (Danvers, MA, USA), Santa Cruz Biotechnology (Dallas, TX, USA), Calbiochem/Merck Millipore (Billerica, MA, USA), and Enzo Life Sciences (Farmingdale, NY, USA). Reagents used for electrophoresis and Western Blot (WB) were purchased from Bio-Rad (Hercules, CA, USA).

Animal experimentation

Two and 14 months-old male mice (hereafter referred as 2 m/o and 14 m/o, respectively) with mixed genetic background B6D2Jrc/Hsd were used throughout this study. Mice were kept in cycles of 12 h of light/dark in temperature (22°C) and humidity-controlled rooms, fed standard chow diet ad libitum and with free access to drinking water. Male animals at the age of 6 months were randomly distributed into control and APAP experimental groups. APAP treated-mice were given an infratherapeutic dose around 57.1 mg/kg/day (Merck-Sigma Aldrich) (equivalent to 324.08 mg/day for a 70 kg adult human) [82] mixed in the drinking water for 8 months (hereafter referred as 14 m/o + APAP). Control (age matched 14 m/o and 2 m/o) mice received regular drinking water. During the treatment, body weight and water consumption were measured weekly. To achieve the desired dosage levels, the concentration of APAP in the drinking water was adjusted weekly according to the body weight and water consumption of each group. At the end of the treatment mice were sacrificed. Blood was collected by decapitating the animals and processed for biochemical parameters. Liver was immediately frozen in liquid nitrogen and stored at -80°C for subsequent molecular analysis, or fixed with 4% paraformaldehyde (PFA) for further histological analysis. All animal experimentation was carried out in accordance with the recommendations of the Federation of European Laboratory Animal Science Associations (FELASA) on health surveillance, the European Community Law (2010/63/UE) and the Spanish Law (RD 53/2013), with the approval of the Ethics Committee of the Bioethics Commission of the CSIC, Spain.

Histopathology assessment

Paraffin-embedded liver biopsy sections (5 μm) were stained with hematoxylin and eosin (H&E) at the CNB Histology Facility (Madrid, Spain) and evaluated by a single blinded hepatopathologist (C. G-M). NAFLD activity score (NAS score) was determined by using the histological evaluation system for animal models previously validated [83]. The degrees of steatosis of hepatocytes were divided into: 0, < 5 %; 1, 5-33 %; 2, > 33-66 %; and 3, > 66 %. The lobular inflammation was divided into: 0, without foci (< 0.5 foci); 1, 0.5-1 foci; 2, 1-2 foci; and 3, > 2 foci. The NAS score was
calculated based on the set of grades of steatosis and lobular inflammation.

**Oil Red O staining**

For Oil Red O staining, pieces of liver were fixed O/N in 4 % PFA and cryoprotected in subsequent gradients of 15 % and 30 % sucrose in PBS at 4°C. After, samples were quickly frozen in Tissue-Tec OCT (Miles) and sectioned at 5 μm using a Leica CM3050 S cryostat. Tissue slices were fixed in ice-cold 10 % formaldehyde (47630, Fluka) for 10 min and washed twice in distilled water. Then, samples were fixed in 1.2 propylene glycol (82280, Merck-Sigma Aldrich) for 10 min at room temperature (RT). Slices were stained in 0.7 % Oil Red O solution (O0625, Merck-Sigma Aldrich) shaking for 7 min. After washing twice in 87 % glycerol (A3739, Panreac AppliChem), sections were counterstained with hematoxylin (H3136, Merck-Sigma Aldrich) solution for 5 s, rinsed again with tap water and mounted in Aquatex (108572, Merck- Millipore).

**Isolation of hepatic non-parenchymal cells (NPCs)**

NPCs were isolated as described previously [78]. Briefly, livers were collected and washed with warm PBS. Immediately, they were transferred to HBSS (Hank’s Balanced Salt solution; Gibco, Life Technologies, Carlsbad, CA, USA) at RT, disintegrated and filtered through 100 μm cell strainers. Then, homogenates were centrifuged at 500 x g for 5 min at RT and cell pellets were resuspended in a 36 % Percoll solution (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) containing 100 UI/mL of heparin (HIBOR 5000 UI, ROVI Contract manufacturing, Madrid, Spain). After centrifugation at 800 x g without brake for 20 min at RT, supernatants were discarded and then erythrocytes were removed from cell pellets by using a red blood cell lysis buffer (150 mM NH₄Cl, 10 mM KHCO₃, 0.1 mM EDTA pH 7.3). The resulting cell pellets were washed with cold HBSS, centrifuged at 500 x g for 5 min at 4°C and, finally, NPCs were resuspended in cold HBSS for further analysis.

**Flow cytometry**

Isolated NPCs were incubated with the following antibodies: Cd45-FITC (1/200) (rat IgG, Beckman, Brea, CA, USA), Ly6g-PE (1/100) (rat IgG2ak Pharmigen, San Jose, CA), F4/80-APC (1/25) (rat IgG2ak, eBioscience, San Diego, CA), Cd11b-Pc7 (1/100) (rat IgG2bk, eBioscience), Cd3-Pc7 (1/100) (hamster IgG, BioLegend, San Diego, CA), NK1.1-APC (1/100) (mouse IgG2ak, Pharmigen), Cd8-PE (1/50) (rat IgMk, Pharmingen), Cd4-PERCy5.5 (1/100) (rat IgG2bK, BioLegend), Ly6c-FITC (1/100) (rat IgG2bK, BioLegend) and Ccr2 (1/200) (rat IgG2bK, BioLegend); or their corresponding isotype controls for 20 min at RT protected from the light. After washing steps, NPCs were resuspended with PBS. Flow cytometry data were acquired with a FACSCanto II and data analysis was performed using Cytomics FC500 with the CXP program. The results were referred to the % Cd45 positive cells, according to each combination.

**Flow cytometry analysis of peripheral blood mononuclear cells (PBMCs)**

Peripheral blood samples were obtained by decapitating the animals and collected with heparin (1000 U/ml, Hospira, ROVI Contract manufacturing, Madrid, Spain). Fifty μl of blood were incubated with the antibodies detailed in the NPCs section for 20 min at RT and protected from the light. Then, erythrocytes were removed by using the red blood cell lysis buffer mentioned above. After 10 min, 2.5 ml of FACS buffer (PBS-0.5 % BSA) were added and samples were centrifuged at 500 x g for 5 min at RT. Cell pellets were washed with FACS buffer and centrifuged again. Cells were resuspended in 200 μl of FACS buffer and then analyzed by flow cytometry after filtration. Flow cytometry data were acquired with a FACSCanto II and data analysis was performed using Cytomics FC500 with the CXP program.

**Alanine transaminase (ALT), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) assays**

The levels of ALT, AST and LDH were determined in plasma by using Reflotron strips (Roche Diagnostics, Barcelona, Spain) for ALT or a specific colorimetric kit according to the manufacturer’s instructions (BioSystems, Barcelona, Spain) for AST and LDH.

**Measurement of intracellular redox state**

Lipid peroxidation (LPO) levels were determined as an indirect measure of the production of reactive oxygen species (ROS). The reaction of thiobarbituric acid (TBA) was used according to Ohkawa et al. to quantify ex vivo the amount of aldehyde products generated by LPO in liver tissue [84]. Liver extracts (25 mg) were homogenized with 300 μl of 0.15 M KCl and then, centrifuged at 1000 x g for 5 min at RT. Supernatants were collected and 50 μl were incubated with 0.26 % TBA pH 3-3.5, 0.4 % SDS and 7.5 % acetic acid for 60 min at 95°C, and after that, centrifuged at 1000 x g for 5 min at RT. A pink chromophore was produced in samples in direct relation to the amount of peroxidized products. The absorbance of the supernatant was measured in a Synergy HT plate reader (BioTek, www.aging-us.com 7812 AGING
Oviglio TO, Italy) at 532 nm. The amount of TBA reactive species (TBARS) (mostly malondialdehyde, MDA) was calculated by interpolation of values in a constructed MDA standard curve with 1,1,3,3-tetramethoxypropane (TMP). Results were expressed as nmol MDA per mg of protein.

**Dihydroethidium (DHE) staining**

In *situ* staining of O$_2^*$ was performed using frozen mice liver biopsy sections as described [85]. Tissue was fixed in 4 % PFA during 24 h, after that it was embedded in sucrose gradient and then frozen in Tissue-Tek OCT and stored at −70°C until use. Frozen liver tissue sections (20–30 µm) were preincubated with a superoxide dismutase mimetic MnTBAP (10 µM, Sigma Aldrich) during 1 h at RT. For *in situ* imaging of O$_2^*•−$, slides were incubated for 30 min in a humidified chamber at 37°C with 5 µM DHE (Molecular Probes, Inc, USA). Images were obtained with a Zeiss 510 laser scanning confocal microscope and fluorescence intensity of liver sections (5 sections per mice, n=5 mice/group) was analyzed with ImageJ software (National Institutes of Health).

**Fluorescent immunohistochemistry**

Livers were dissected and fixed in 4 % PFA O/N at 4°C. Livers were transferred to 15 % sucrose in PBS and 30 % sucrose in PBS at 4°C until tissue sunk and, then embedded in Tissue-tek OCT. For immunofluorescence, 5 µm OCT tissue cryosections were stained with anti-Cd8 antibody (#550281, BD), incubated with donkey anti-rat Alexa Fluor 595 secondary antibody (#A21209, Thermofisher) and counterstained with DAPI. Random field (6 per mice) were collected using a Nikon Eclipse 90i microscope and positively stained cells were quantified using ImageJ Software (NIH).

**Chromogenic immunohistochemistry**

Livers were dissected and fixed in 4 % PFA O/N at 4°C and embedded in paraffin. Sections of 5 µm thickness were cut and stained with anti-Ly6c antibody (provided by A. Castrillo, CSIC, Spain), incubated with biotin-conjugated rabbit anti-rat secondary antibody (#BA-4000, Vector) and counterstained with Harris Hematoxylin. Random fields (6 per mice) were obtained using a Zeiss AxioPhot microscope and positively stained cells were quantified using ImageJ Software (NIH).

**RNA extraction and quantitative polymerase chain reaction (qPCR) analysis**

Total RNA from liver samples was extracted using TRIzol reagent (Thermofisher Scientific, MA, USA), and treated with DNase for 10 min according to the manufacturer’s instructions. Equal amounts (250 ng) of RNA were reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Thermofisher Scientific) as follows: 25°C, 10 min; 37°C, 2 h; 85°C, 5 min. Quantitative PCR (qPCR) was performed with 50 ng of cDNA mixed with Power SYBR Green Master Mix (Thermofisher Scientific) for primers (Table 1) or with Taqman Universal Master Mix II (Thermofisher Scientific) for Taqman probes (Table 1). Amplification was conducted in a 7900HT Fast-Real Time PCR System (Life Technologies). PCR cycles proceeded as follows: initial denaturation for 10 min at 95°C and then 40 cycles of 15 s at 95°C and 1 min at 60°C. For qPCR using SYBR Green Master Mix, the dissociation curve was performed as follows: 15 s at 95°C; 15 s at 60°C; and 15 s at 95°C, in order to confirm the specificity of the PCR products. Data analysis is based on the ΔΔCt method with normalization of the raw data to the housekeeping gene Hypoxanthine phosphoribosyltransferase 1 (Hprt1), as described in the manufacturer’s manual (Life Technologies). Each sample was analyzed in duplicate.

**Homogenization and preparation of tissue extracts and western blotting**

Liver tissue (30-50 mg) was homogenized in ice-cold lysis buffer containing 0.5 % CHAPS, 10 mM Tris-HCl pH 7.5, 1 mM MgCl$_2$, 1 mM EDTA, 10 % glycerol and protease and phosphatase inhibitors (5726, P0044, P8340, Merck-Sigma Aldrich) using the Brinkman PT 10/35 Polytron. Extracts were then incubated for 45 min at 4°C with continuous agitation. Liver extracts were cleared by centrifugation at 13000 x g for 15 min at 4°C. Protein determination was performed by the Bradford dye method, using the Bio-Rad reagent and bovine serum albumin (BSA) (Merck-Sigma Aldrich) as the standard. Absorbance was measured in a Synergy HT plate reader at 595 nm.

Cytosolic and nuclear extracts were isolated from 25 mg of tissue as follows. Livers were disrupted in 0.3 M sucrose solution containing the protease and phosphatase inhibitors mentioned above by using a micro pestle. Homogenates were centrifuged at 1000 x g for 10 min at 4°C to separate the cytosolic fraction (supernatant) and the nuclear fraction (pellet). Supernatants containing the cytosolic fraction were centrifuged 3 times at 27000 x g for 15 min at 4°C, and transferred to a new tube for protein analysis. Pellets containing the nuclear fraction were washed with 0.3 M sucrose solution and centrifuged at 1000 x g for 10 min at 4°C. After three washing steps, pellets were then resuspended in RIPA buffer (Merck-Sigma Aldrich) and incubated for 1 h at 4°C on a rotating mixer. After
Table 1. List of primers used for qPCR analysis.

| Gene          | Taqman reference/ Primer sequence 5′→ 3′ |
|---------------|-----------------------------------------|
| Arg1          | Mm00475988_m1                           |
| Hprt1         | Mm00446968_m1                           |
| Clec10a (encoding MGL1) | F: 5′-TGAGAAAGGCTTTAAGAAGCTGGG-3′  |
|               | R: 5′-GACCACTTGTAGTGATGTCG-3′          |
| Hmox1 (encoding HO-1) | F: 5′-AGGCTAAGAGGCTTTAAGCCTGG-3′    |
|               | R: 5′-TGCTCACTCAGTCATCA-3′             |
| Nfe2l2 (encoding NRF2) | F: 5′-AGACGATAGGTTTGGGCATA-3′        |
|               | R: 5′-GCCAAACTTGCTTCATGTCG-3′          |
| Sod2 (encoding MnSOD) | F: 5′-ACACGATAGGTTTGGGCATA-3′        |
|               | R: 5′-GCCAAACTTGCTTCATGTCG-3′          |
| Nqo1          | F: 5′-GTCCATTCCAGCTGACCA-3′            |
|               | R: 5′-TTGCCCTGAGGCTCTCTATGC-3′         |
| Ccl2 (encoding MCP1) | F: 5′-AAAAACCTGGATCGGAACCAA-3′       |
|               | R: 5′-CGGGTCAACTTCACATTCAGAAG-3′       |
| Hprt1         | F: 5′-GAGGAATCCCTGTGATGTTGCG-3′        |
|               | R: 5′-GGCTGGGCGCTATAGGCTTAG-3′         |

sonication, cellular debris was removed by centrifugation at 8000 x g for 15 min at 4°C and the supernatants containing the nuclear fraction were collected. Protein determination was performed using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific) and a standard curve of BSA. Absorbance was measured in a Synergy HT plate reader at 562 nm.

For protein analysis, protein extracts (30 μg) were boiled for 5 min with Laemmli buffer (200 mM Tris-HCl pH 6.8, 5.2 % SDS, 40 % glycerol, 3 % β-mercaptoethanol, and 0.08 % bromophenol blue) and then separated by 12 % SDS-PAGE (80 V-120 V, 2 h). Proteins were transferred to a polyvinylidene fluoride membrane (PVDF) using a semi-dry method (Trans-blot SD SEMI-Dry Electrophoresis Transfer Cell, Bio-Rad; 25 V and 1.5 A, 37 min). Membranes were blocked using 5 % non-fat dried milk in PBS for 1 h at RT and then incubated with primary antibodies in PBS (Table 2) overnight at 4°C. After 3 washes with PBS containing 0.1 % Tween-20, membranes were incubated with the corresponding peroxidase-conjugated secondary antibodies (anti-rabbit, 1/5000, Bio-Rad; anti-goat, 1/50000, Merck-Sigma Aldrich) for 1 h at RT. Immunoreactive bands were visualized using the ECL Western blotting protocol. Blots were normalized by lane charge using antibodies against GAPDH, VINCULIN or LAMIN B, as indicated in each figure. Different exposure times were used for each membrane to ensure the linearity of the intensity of the bands. The densitometric analysis was carried out with the ImageJ program and was expressed in arbitrary units.

**Glucose and pyruvate tolerance tests (GTT, PTT)**

For glucose tolerance tests, 16 h fasted mice received an intraperitoneal (i.p.) injection of 2 g D-glucose/kg body weight. Glucose concentration in blood was measured with an Accu-Check glucometer (Roche Diagnostics) at 0, 15, 30, 60, 90 and 120 min time points, and the area under the curve (AUC) was calculated. Pyruvate tolerance tests were performed similarly, except that the mice received an i.p. injection of 1.5 g sodium pyruvate/kg body weight.

**Data analysis**

Statistical analysis was performed using Kruskal-Wallis, one-way ANOVA or Brown-Forsythe and Welch ANOVA tests, followed by Dunn, Bonferroni or Tamhane T2 post-hoc tests, respectively. Non-parametric Mann-Whitney U test was also used. The results were expressed as the mean ± standard error (S.E.M.) of at least four-six animals. To explore the effect to APAP treatment in body weight throughout the treatment, mixed ANOVA of repeated measures was used to analyze the effect on the age, treatment and the age-treatment interaction. The Mauchly sphericity test was used to test the sphericity hypothesis. In the case of rejection, the analyses were based on the Greenhouse-Geisser multivariate test. The analysis was performed
Table 2. List of primary antibodies used for analysis by WB.

| Detects | Commercial manufacturer | Reference |
|---------|-------------------------|-----------|
| pERK1/2 | Cell Signaling          | 4370P     |
| ERK1/2  | Cell Signaling          | 9102S     |
| pp38    | Cell Signaling          | 9211S     |
| p38     | Cell Signaling          | 9212      |
| HO-1    | Merck Millipore         | AB1284    |
| MnSOD   | Enzo Life Sciences      | ADI-SOD-MOF |
| NQO1    | Cell Signaling          | 3187      |
| VINCULIN| Santa Cruz Biotechnology| sc-73614  |
| GAPDH   | Merck-Sigma Aldrich     | G9545     |
| NRF2    | Kindly provided by Dr. Cuadrado (UAM, Spain) |     |
| p65-NF-κB| Cell Signaling         | 8242      |
| LAMIN B | Santa Cruz Biotechnology| sc-6217  |
| pIkBα   | Cell Signaling          | 9246      |
| IkBα    | Cell Signaling          | 9242      |

with the GraphPad Prism 8 program. The level of significance was defined as *P < 0.05.*

**Abbreviations**

APAP: N-acetyl-p-aminophenol, acetaminophen or paracetamol; CRP: C-reactive Protein; ERK: extracellular-signal-regulated kinase; GLUT4: glucose transporter type 4; HO-1/Hmox1: heme oxygenase 1; IkBα: nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; IL: interleukin; JNK: c-Jun N-terminal kinase; MCP1/Ccl2: monocyte chemotactant protein 1; MGL1/Clec10a: macrophage galactose-type lectin 1; MnSOD/Sod2: manganese superoxide dismutase/superoxide dismutase 2; NK: natural killer; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NQO1: NAD(P)H quinone dehydrogenase 1; NRF2/Nfe2l2: nuclear factor erythroid 2-related factor 2; p38-MAPK: p38 mitogen-activated protein kinases; sICAM-1: soluble intercellular adhesion molecule-1; SIRT1: sirtuin 1; sVCAM-1: soluble vascular cell adhesion molecule-1; TNF-α: tumor necrosis factor-α.

**AUTHOR CONTRIBUTIONS**

R.B., M.P.V., P.R., R.A., M. F-A conducted the experiments. C. G-M analyzed liver biopsies. M.C. and L.B. contributed with suggestions and critical revision of the manuscript. R.B., M.P.V., P.R., M. S, A.M.V. wrote the manuscript. P. M-S and A.M.V. supervised the study. All authors revised and approved the final version of the manuscript.

**ACKNOWLEDGMENTS**

We acknowledge Laura Molero (Universidad Autónoma de Madrid, Spain) for the technical assistance with flow cytometry analysis and A. Castrillo and A. Cuadrado (IIBm, Spain) for providing Cd8 and NRF2 antibodies, respectively.

**CONFLICTS OF INTEREST**

The authors declare that they have no conflicts of interest.

**FUNDING**

SAF2016-75004-R, PID2019-108977RB-100 (AEI/FEDER, UE) to P. M-S, and M.C. and S2017/BMD-3686 (CM) to P. M-S, RTI2018-094052-B-100 (AEI/FEDER, UE), S2017/BMD-3684 (CM), Fundación Ramón Areces (Spain) and CIBERdem (ISCIII) to A.M.V., and PI17/00535 (ISCIII/FEDER, UE) to C. G-M.

**REFERENCES**

1. Bacon BR, O’Grady JG, Di Bisceglie AM, Lake JR. Comprehensive Clinical Hepatology. Elsevier Ltd; 2006.
2. Premoli A, Paschetta E, Hvalryg M, Spandre M, Bo S, Durazzo M. Characteristics of liver diseases in the elderly: a review. Minerva Gastroenterol Dietol. 2009; 55:71–78. PMID: 19212309
3. Kim IH, Xu J, Liu X, Koyama Y, Ma HY, Diggle K, You YH, Schilling JM, Jeste D, Sharma K, Brenner DA, Kisseleva T. Aging increases the susceptibility of hepatic inflammation, liver fibrosis and aging in response to high-fat diet in mice. Age (Dordr). 2016; 38:291–302. https://doi.org/10.1007/s11357-016-9938-6 PMID: 27578257
4. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani GC, Salvioli S. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007; 128:92–105. 
https://doi.org/10.1016/j.mad.2006.11.016  
PMID: 17116321

5. Franceschi C, Zaikin A, Gordleeva S, Ivanchenko M, Bonifazi F, Storci G, Bonafé M. Inflammaging 2018: an update and a model. Semin Immunol. 2018; 40:1–5. 
https://doi.org/10.1016/j.smim.2018.10.008  
PMID: 30392751

6. Franceschi C, Bonafé M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000; 908:244–54. 
https://doi.org/10.1111/j.1749-6632.2000.tb06651.x  
PMID: 10911963

7. Calder PC, Bosco N, Bourdet-Sicard R, Capuron L, Delzenne N, Doré J, Franceschi C, Lehtinen MJ, Recker T, Salvioli S, Visioli F. Health relevance of the modification of low grade inflammation in ageing (inflammaging) and the role of nutrition. Ageing Res Rev. 2017; 40:95–119. 
https://doi.org/10.1016/j.arr.2017.09.001  
PMID: 28899766

8. Vallejo AN. Immune remodeling: lessons from repertoire alterations during chronological aging and in immune-mediated disease. Trends Mol Med. 2007; 13:94–102. 
https://doi.org/10.1016/j.molmed.2007.01.005  
PMID: 17267287

9. Swain S, Clise-Dwyer K, Haynes L. Homeostasis and the age-associated defect of CD4 T cells. Semin Immunol. 2005; 17:370–77. 
https://doi.org/10.1016/j.smim.2005.05.007  
PMID: 15964201

10. Tarazona R, DelaRosa O, Alonso C, Ostos B, Espejo J, Peña J, Solana R. Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev. 2000; 121:77–88. 
https://doi.org/10.1016/s0047-6374(00)00199-8  
PMID: 11164462

11. Taniguchi M, Seino K, Nakayama T. The NKT cell system: bridging innate and acquired immunity. Nat Immunol. 2003; 4:1164–65. 
https://doi.org/10.1038/ni1203-1164  
PMID: 14639465

12. Emoto M, Miyamoto M, Emoto Y, Zerrahn J, Kaufmann SH. A critical role of T-cell receptor gamma/delta cells in antibacterial protection in mice early in life. Hepatology. 2001; 33:887–93. 
https://doi.org/10.1053/jhep.2001.23504  
PMID: 11283853

13. Watanabe H, Miyaji C, Seki S, Abo T. C-kit+ stem cells and thymocyte precursors in the livers of adult mice. J Exp Med. 1996; 184:687–93. 
https://doi.org/10.1084/jem.184.2.687  
PMID: 8760822

14. Haas JT, Vonghia L, Moglenko DA, Verrijken A, Molendi-Coste O, Fleury S, Deprince A, Nikitin A, Wottrain E, Ducrocq-Geoffroy L, Pic S, Derudas B, Dehont H, et al. Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution. Nat Metab. 2019; 1:604–14. 
https://doi.org/10.1038/s42255-019-0076-1  
PMID: 31701087

15. Sutti S, Albano E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 2020; 17:81–92. 
https://doi.org/10.1038/s41575-019-0210-2  
PMID: 31605031

16. Tittarelli R, Pellegrini M, Scarpellini MG, Marinelli E, Bruti V, Di Luca NM, Busardo FP, Zaami S. Hepatotoxicity of paracetamol and related fatalities. Eur Rev Med Pharmacol Sci. 2017; 21:95–101. 
PMID: 28379590

17. Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol. 2010; 196:369–405. 
https://doi.org/10.1007/978-3-642-00663-0_12  
PMID: 20020268

18. Speiser JL, Karvellas CJ, Wolf BJ, Chung D, Koch DG, Durkalski VL. Predicting daily outcomes in acetaminophen-induced acute liver failure patients with machine learning techniques. Comput Methods Programs Biomed. 2019; 175:111–20. 
https://doi.org/10.1016/j.cmpb.2019.04.012  
PMID: 31104700

19. Chiew AL, James LP, Isbister GK, Pickering JW, McArule K, Chan BS, Buckley NA. Early acetaminophen-protein adducts predict hepatotoxicity following overdose (ATOM-5). J Hepatol. 2020; 72:450–62. 
https://doi.org/10.1016/j.jhep.2019.10.030  
PMID: 31760072

20. Kaplowitz N. Acetaminophen hepatotoxicity: what do we know, what don’t we know, and what do we do next? Hepatology. 2004; 40:23–26. 
https://doi.org/10.1002/hep.20312  
PMID: 15239082

21. Rada P, Pardo V, Mobasher MA, García-Martínez I, Ruiz L, González-Rodríguez Á, Sanchez-Ramos C, Muntané J, Alemany S, James LP, Simpson KJ, Monsalve M,
Valdecantos MP, Valverde ÁM. SIRT1 controls acetaminophen hepatotoxicity by modulating inflammation and oxidative stress. Antioxid Redox Signal. 2018; 28:1187–208. https://doi.org/10.1089/ars.2017.7373 PMID:29084443

22. Motiño O, Agra N, Brea Contreras R, Dominguez-Moreno M, García-Monzón C, Vargas-Castrillón J, Carnovale CE, Boscá L, Casado M, Mayoral R, Valdecantos MP, Valverde ÁM, Francés DE, Martín-Sanz P. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice. Biochim Biophys Acta. 2016; 1862:1710–23. https://doi.org/10.1016/j.bbadis.2016.06.009 PMID:27321932

23. Francés DE, Motiño O, Agrá N, González-Rodríguez Á, Fernández-Álvarez A, Cucarella C, Mayoral R, Castro-Sánchez L, García-Casarrubios E, Boscá L, Carnovale CE, Casado M, Valverde ÁM, Martín-Sanz P. Hepatic cyclooxygenase-2 expression protects against diet-induced steatosis, obesity, and insulin resistance. Diabetes. 2015; 64:1522–31. https://doi.org/10.2337/db14-0979 PMID:25422106

24. Liu CY, Chang CW, Lee HC, Chen YJ, Tsai TH, Chiau JSC, Wang TE, Tsai MC, Yeung CY, Shih SC. Metabolic damage presents differently in young and early-aged C57BL/6 mice fed a high-fat diet. Int J Gerontol. 2016; 10:105–11. https://doi.org/10.1016/j.jige.2015.10.004

25. Nguyen P, Valanejad L, Cast A, Wright M, Garcia JM, El-Serag HB, Karns R, Timchenko NA. Elimination of age-associated hepatic steatosis and correction of aging phenotype by inhibition of cdk4-C/EBPα-p300 axis. Cell Rep. 2018; 24:1597–609. https://doi.org/10.1016/j.celrep.2018.07.014 PMID:30089269

26. Ros M, Carrascosa JM. Current nutritional and pharmacological anti-aging interventions. Biochim Biophys Acta Mol Basis Dis. 2020; 1866:165612. https://doi.org/10.1016/j.bbadis.2019.165612 PMID:31816437

27. Nguyen NU, Stamper BD. Polyphenols reported to shift APAP-induced changes in MAPK signaling and toxicity outcomes. Chem Biol Interact. 2017; 277:129–36. https://doi.org/10.1016/j.cbi.2017.09.007 PMID:28918124

28. Mobasher MA, González-Rodriguez A, Santamaría B, Ramos S, Martín MÁ, Goya L, Rada P, Letzig L, James LP, Cuadrao A, Martín-Pérez J, Simpson KJ, Muntané J, Valverde AM. Protein tyrosine phosphatase 1B modulates GSK3β/Nrf2 and IGFIR signaling pathways in acetaminophen-induced hepatotoxicity. Cell Death Dis. 2013; 4:e626. https://doi.org/10.1038/cddis.2013.150 PMID:23661004

29. Xu JJ, Hendriks BS, Zhao J, de Graaf D. Multiple effects of acetaminophen and p38 inhibitors: towards pathway toxicology. FEBS Lett. 2008; 582:1276–82. https://doi.org/10.1016/j.febslet.2008.01.063 PMID:18282474

30. Ding Y, Li Q, Xu Y, Chen Y, Deng Y, Zhi F, Qian K. Attenuating oxidative stress by paenol protected against acetaminophen-induced hepatotoxicity in mice. PLoS One. 2016; 11:e0154375. https://doi.org/10.1371/journal.pone.0154375 PMID:27144271

31. Long X, Song J, Zhao X, Zhang Y, Wang H, Liu X, Suo H. Silkworm pupa oil attenuates acetaminophen-induced acute liver injury by inhibiting oxidative stress-mediated NF-κB signaling. Food Sci Nutr. 2019; 8:237–45. https://doi.org/10.1002/fsn3.1296 PMID:31993149

32. Maes M, Vinken M, Jaeschke H. Experimental models of hepatotoxicity related to acute liver failure. Toxicol Appl Pharmacol. 2016; 290:86–97. https://doi.org/10.1016/j.taap.2015.11.016 PMID:26631581

33. Jaeschke H, Xie Y, McGill MR. Acetaminophen-induced liver injury: from animal models to humans. J Clin Transl Hepatol. 2014; 2:153–61. https://doi.org/10.14218/JCTH.2014.00014 PMID:26355817

34. Woolbright BL, Jaeschke H. Role of the inflamasome in acetaminophen-induced liver injury and acute liver failure. J Hepatol. 2017; 66:836–48. https://doi.org/10.1016/j.jhep.2016.11.017 PMID:27913221

35. Mobasher MA, de Toro-Martín J, González-Rodríguez Á, Ramos S, Letzig LG, James LP, Muntané J, Álvarez C, Valverde ÁM. Essential role of protein-tyrosine phosphatase 1B in the modulation of insulin signaling by acetaminophen in hepatocytes. J Biol Chem. 2014; 289:29406–19. https://doi.org/10.1074/jbc.M113.539189 PMID:25204659

36. Houtkooper RH, Argmann C, Houten SM, Cantó C, Jeninga EH, Andreux PA, Thomas C, Doenlen R, Schoonjans K, Auwerx J. The metabolic footprint of aging in mice. Sci Rep. 2011; 1:134. https://doi.org/10.1038/srep00134 PMID:22355651

37. Fox J, Barthold S, Davisson M, Newcomer C, Quimby F, Smith A, editors. The Mouse in Biomedical Research. 2nd edition. 2006. p. 392.
38. Fengler VH, Macheiner T, Kessler SM, Czepukojc B, Gemperlein K, Müller R, Kiemer AK, Magnes C, Haybaeck J, Lackner C, Sargsyan K. Susceptibility of different mouse wild type strains to develop diet-induced NAFLD/AFLD-associated liver disease. PLoS One. 2016;11:e0155163. https://doi.org/10.1371/journal.pone.0155163 PMID:27167736

39. Sundberg JP, Berndt A, Sundberg BA, Silva KA, Kennedy V, Smith RS, Cooper TK, Schofield PN. Approaches to investigating complex genetic traits in a large-scale inbred mouse aging study. Vet Pathol. 2016;53:456–67. https://doi.org/10.1177/0300985815612556 PMID:26936752

40. West DB, Boozer CN, Moody DL, Atkinson RL. Dietary obesity in nine inbred mouse strains. Am J Physiol. 1992;262:R1025–32. PMID:1621856

41. González-Rodríguez A, Máis-Gutierrez JA, Mirasierra M, Fernandez-Pérez A, Lee YJ, Ko HJ, Kim JK, Romanos E, Carrascosa JM, Ros M, Vallejo M, Rondinone CM, Valverde AM. Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging. Aging Cell. 2012;11:284–96. https://doi.org/10.1111/j.1474-9726.2011.00786.x PMID:22221695

42. Shan Z, Alvarez-Sola G, Uriarte I, Arechederra M, Fernández-Barrena MG, Berasain C, Ju C, Avila MA. Fibroblast growth factors 19 and 21 in acute liver damage. Ann Transl Med. 2018;6:257. https://doi.org/10.21037/atm.2018.05.26 PMID:30069459

43. Huang M, Williams J, Kong B, Zhu Y, Li G, Zhu Z, Guo GL. Fibroblast growth factor 15 deficiency increases susceptibility but does not improve repair to acetaminophen-induced liver injury in mice. Dig Liver Dis. 2018;50:175–80. https://doi.org/10.1016/j.dld.2017.08.023 PMID:28867475

44. Gan L, Chitturi S, Farrell GC. Mechanisms and implications of age-related changes in the liver: nonalcoholic fatty liver disease in the elderly. Curr Gerontol Geriatr Res. 2011;2011:831536. https://doi.org/10.1155/2011/831536 PMID:21918648

45. Sousa-Victor P, Neves J, Cedron-Craft W, Ventura PB, Liao CY, Riley RR, Soifer I, van Bruggen N, Kolumam GA, Villeda SA, Lamba DA, Jasper H. MANF regulates metabolic and immune homeostasis in ageing and protects against liver damage. Nat Metab. 2019;1:276–90. https://doi.org/10.1038/s42255-018-0023-6 PMID:31489403

46. Hunt NJ, Kang SW, Lockwood GP, Le Couteur DG, Cogger VC. Hallmarks of aging in the liver. Comput Struct Biotechnol J. 2019;17:1151–61. https://doi.org/10.1016/j.csbj.2019.07.021 PMID:31462971

47. Shih PH, Yen GC. Differential expressions of antioxidant status in aging rats: the role of transcriptional factor Nrf2 and MAPK signaling pathway. Biogerontology. 2007;8:71–80. https://doi.org/10.1007/s10522-006-9033-y PMID:16850181

48. Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, Liu RM, Hagen TM. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci USA. 2004;101:3381–86. https://doi.org/10.1073/pnas.0400282101 PMID:14985508

49. Sykiotis GP, Habeos IG, Samuelson AV, Bohmann D. The role of the antioxidant and longevity-promoting Nrf2 pathway in metabolic regulation. Curr Opin Clin Nutr Metab Care. 2011;14:41–48. https://doi.org/10.1097/MCO.0b013e32834136f2 PMID:21102319

50. Kamzalov S, Sohal RS. Effect of age and caloric restriction on coenzyme Q and alpha-tocopherol levels in the rat. Exp Gerontol. 2004;39:1199–203. https://doi.org/10.1016/j.exger.2004.04.007 PMID:15288694

51. Mach J, Huizer-Pajkos A, Cogger VC, McKenzie C, Le Couteur DG, Jones BE, de Cabo R, Hilmer SN. The effect of aging on acetaminophen pharmacokinetics, toxicity and Nrf2 in fischer 344 rats. J Gerontol A Biol Sci Med Sci. 2014;69:387–97. https://doi.org/10.1093/gerona/glt095 PMID:23863315

52. Kane AE, Mitchell SJ, Mach J, Huizer-Pajkos A, McKenzie C, Jones B, Cogger V, Le Couteur DG, de Cabo R, Hilmer SN. Acetaminophen hepatotoxicity in mice: effect of age, frailty and exposure type. Exp Gerontol. 2016;73:95–106. https://doi.org/10.1016/j.exger.2015.11.013 PMID:26615879

53. Lavrovsky Y, Song CS, Chatterjee B, Roy AK. Age-dependent increase of heme oxygenase-1 gene expression in the liver mediated by NFKappaB. Mech Ageing Dev. 2000;114:49–60. https://doi.org/10.1016/s0047-6374(00)0087-7 PMID:10731581
54. Bloomer SA, Zhang HJ, Brown KE, Kregel KC. Differential regulation of hepatic heme oxygenase-1 protein with aging and heat stress. J Gerontol A Biol Sci Med Sci. 2009; 64:419–25. 
https://doi.org/10.1093/gerona/gln056  
PMID: 19196643

55. Chiu H, Brittingham JA, Laskin DL. Differential induction of heme oxygenase-1 in macrophages and hepatocytes during acetaminophen-induced hepatotoxicity in the rat: effects of hemin and biliverdin. Toxicol Appl Pharmaco. 2002; 181:106–15.  
https://doi.org/10.1006/taap.2002.9409  
PMID: 12051994

56. Bauer I, Vollmar B, Jaeschke H, Rensing H, Kraemer T, Larsen R, Bauer M. Transcriptional activation of heme oxygenase-1 and its functional significance in acetaminophen-induced hepatitis and hepatocellular injury in the rat. J Hepatol. 2000; 33:395–406.  
https://doi.org/10.1016/s0168-8278(00)80275-5  
PMID: 11019995

57. Immenschoer S, Ramadori G. Gene regulation of heme oxygenase-1 as a therapeutic target. Biochem Pharmacol. 2000; 60:1121–28.  
https://doi.org/10.1016/s0006-2952(00)00443-3  
PMID: 11007950

58. Farombi EO, Surh YJ. Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J Biochem Mol Biol. 2006; 39:479–91.  
https://doi.org/10.5483/bmbrep.2006.39.5.479  
PMID: 17002867

59. Ramachandran A, Lebofsky M, Weinman SA, Jaeschke H. The impact of partial manganese superoxide dismutase (SOD2)-deficiency on mitochondrial oxidant stress, DNA fragmentation and liver injury during acetaminophen hepatotoxicity. Toxicol Appl Pharmaco. 2011; 251:226–33.  
https://doi.org/10.1016/j.taap.2011.01.004  
PMID: 21241772

60. Fujimoto K, Kumagai K, Ito K, Arakawa S, Ando Y, Oda S, Yamoto T, Manabe S. Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen. Toxicol Pathol. 2009; 37:193–200.  
https://doi.org/10.1177/0192623308329282  
PMID: 19332662

61. Moffitt JS, Aleksunes LM, Kardas MJ, Slitt AL, Klaassen CD, Manautou JE. Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen. Toxicology. 2007; 230:197–206.  
https://doi.org/10.1016/j.tox.2006.11.052  
PMID: 17188792

62. Miao L, St Clair DK. Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med. 2009; 47:344–56.  
https://doi.org/10.1016/j.freeradbiomed.2009.05.018  
PMID: 19477268

63. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev. 2006; 86:583–650.  
https://doi.org/10.1152/physrev.00011.2005  
PMID: 16601269

64. Jaiswal AK. Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radic Biol Med. 2000; 29:254–62.  
https://doi.org/10.1016/s0891-5849(00)00306-3  
PMID: 11035254

65. Yan L. Positive oxidative stress in aging and aging-related disease tolerance. Redox Biol. 2014; 2:165–69.  
https://doi.org/10.1016/j.redox.2014.01.002  
PMID: 25460727

66. Gems D, Partridge L. Stress-response hormesis and aging: “that which does not kill us makes us stronger”. Cell Metab. 2008; 7:200–03.  
https://doi.org/10.1016/j.cmet.2008.01.001  
PMID: 18316025

67. Rattan SI. Hormesis in aging. Ageing Res Rev. 2008; 7:63–78.  
https://doi.org/10.1016/j.arr.2007.03.002  
PMID: 17964227

68. Son Y, Cheong YK, Kim NH, Chung HT, Kang DG, Pae HO. Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways? J Signal Transduct. 2011; 2011:792639.  
https://doi.org/10.1155/2011/792639  
PMID: 21637379

69. Hsieh CC, Papaconstantinou J. The effect of aging on p38 signaling pathway activity in the mouse liver and in response to ROS generated by 3-nitropionic acid. Mech Ageing Dev. 2002; 123:1423–35.  
https://doi.org/10.1016/s0047-6374(02)00084-2  
PMID: 12425949

70. Hsieh CC, Rosenblatt JI, Papaconstantinou J. Age-associated changes in SAPK/JNK and p38 MAPK signaling in response to the generation of ROS by 3-nitropionic acid. Mech Ageing Dev. 2003; 124:733–46.  
https://doi.org/10.1016/s0047-6374(03)00083-6  
PMID: 12782417

71. Salminen A, Huuskonen J, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Activation of innate immunity system during aging: NF-κB signaling is the molecular culprit of inflamming-aging. Ageing Res Rev. 2008; 7:83–105.
https://doi.org/10.1016/j.arr.2007.09.002
PMID: 17964225

72. Pfeiffer E, Kegel V, Zeiunger K, Hengstler JG, Nüssler AK, Seehofer D, Damm G. Featured article: isolation, characterization, and cultivation of human hepatocytes and non-parenchymal liver cells. Exp Biol Med (Maywood). 2015; 240:645–56. https://doi.org/10.1177/1535370214558025
PMID: 25394621

73. Mariani E, Roda P, Mariani AR, Vitale M, Degrassi A, Papa S, Facchini A. Age-associated changes in CD8+ and CD16+ cell reactivity: clonal analysis. Clin Exp Immunol. 1990; 81:479–84. https://doi.org/10.1111/j.1365-2249.1990.tb05359.x
PMID: 2144486

74. Bruzzi S, Sutti S, Giudici G, Burlone ME, Ramavath NN, Toscani A, Bozzola C, Schneider P, Morello E, Parola M, Pirisi M, Albano E. B2-lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD). Free Radic Biol Med. 2018; 124:249–59. https://doi.org/10.1016/j.freeradbiomed.2018.06.015
PMID: 29920340

75. Valdecantos MP, Pardo V, Ruiz L, Castro-Sánchez L, Lanzón B, Fernández-Millán E, García-Monzón C, Arroba AI, González-Rodríguez Á, Escrivá F, Álvarez C, Rupérez FJ, Barbas C, et al. A novel glucagon-like peptide 1/glucacon receptor dual agonist improves steatohepatitis and liver regeneration in mice. Hepatology. 2017; 65:950–68. https://doi.org/10.1002/hep.28962 PMID: 27880981

76. Valdecantos MP, Ruiz L, Pardo V, Castro-Sanchez L, García-Monzón C, Lanzón B, Rupérez J, Barbas C, Naylor J, Tреваскис JL, Grimsby J, Rondinone CM, Valverde ÁM. Differential effects of a glucagon-like peptide 1 receptor agonist in non-alcoholic fatty liver disease and in response to hepatectomy. Sci Rep. 2018; 8:16461. https://doi.org/10.1038/s41598-018-33949-z
PMID: 30405191

77. Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, ElGindi M, Han M, Thornton AM, Zhang H, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016; 531:253–57. https://doi.org/10.1038/nature16969 PMID: 26934227

78. González-Rodríguez Á, Valdecantos MP, Rada P, Addante A, Barahona I, Rey E, Pardo V, Ruiz L, Laiglesia LM, Moreno-Aliaga MJ, García-Monzón C, Sánchez A, Valverde ÁM. Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis. Mol Metab. 2018; 7:123–46. https://doi.org/10.1016/j.molmet.2017.10.008
PMID: 29126873

79. Bhattacharjee J, Kirby M, Softic S, Miles L, Salazar-Gonzalez RM, Shivakumar P, Kohli R. Hepatic natural killer T-cell and CD8+ T-cell signatures in mice with nonalcoholic steatohepatitis. Hepatol Commun. 2017; 1:299–310. https://doi.org/10.1002/hep4.1041
PMID: 29152605

80. Tajiri K, Shimizu Y, Tsuneyama K, Sugiyama T. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2009; 21:673–80. https://doi.org/10.1097/MEG.0b013e32831bc3d6
PMID: 19318971

81. Obstfeld AE, Sugaru E, Thearle M, Francisco AM, Gayet C, Ginsberg HN, Ables EV, Ferrante AW Jr. C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes. 2010; 59:916–25. https://doi.org/10.2337/db09-1403
PMID: 20103702

82. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016; 7:27–31. https://doi.org/10.4103/0976-0105.177703
PMID: 27057123

83. Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R, Havekes LM, Kleemann R, van den Hoek AM. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One. 2014; 9:e115922. https://doi.org/10.1371/journal.pone.0115922
PMID: 25539591

84. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979; 95:351–58. https://doi.org/10.1016/0003-2697(79)90738-3
PMID: 36810

85. Abdalla MY, Mathaas MM, Ahmad IM. Reduced heme oxygenase-1 expression in steatotic livers infected with hepatitis C virus. Eur J Intern Med. 2012; 23:649–55. https://doi.org/10.1016/j.ejim.2012.05.001
PMID: 22939811
Supplementary Figure 1. Chronic APAP exposure at an infratherapeutic dose did not alter glucose homeostasis in 14 m/o mice. (A) GTT from 2 m/o, 14 m/o and 14 m/o + APAP mice. Values showing blood glucose (mg/dl) correspond to mean ± S.E.M. (n = 18-22 mice per group). (B) Graph depicts the area under the curve (AUC) from (A). (C) PTT from 2 m/o, 14 m/o and 14 m/o + APAP mice. Values showing blood glucose (mg/dl) correspond to mean ± S.E.M. (n = 17-22 mice per group). (D) Graph depicts the area under the curve (AUC) from (C).
Supplementary Figure 2. Impact of chronic APAP treatment in NRF2 and NF-κB signaling pathways. Representative immunoblots showing nuclear NRF2 and p65-NF-κB level using LAMIN B as a loading control, and cytosolic p-IκBα vs. total IκBα. Graphs depict densitometric quantifications of the indicated protein levels. Values are mean ± S.E.M. (n = 6-8 mice per group) (see original western blot in Supplementary Figure 8). Statistical analysis was performed by one-way ANOVA or Brown-Forsythe and Welch ANOVA test followed by their respective post-hoc test.

Supplementary Figure 3. Quantification of Cd8 positive cells in liver sections from 14 m/o and 14 m/o + APAP mice by immunofluorescence. (A) Representative images of anti-Cd8 staining performed on various livers cryosections from 14 m/o and 14 m/o + APAP mice. (B) Quantification of Cd8+ cells per HPF (High Power Field). Data are represented as the mean ± S.E.M. (n = 4-6 mice per group). Statistical analysis was performed by Mann-Whitney U test.
Supplementary Figure 4. Aging and chronic APAP treatment did not affect non-lymphoid populations in NPCs. Analysis of different inflammatory populations in liver NPCs from 2 m/o, 14 m/o and 14 m/o + APAP mice by flow cytometry. (A) Percentage of Ccr2+Ly6c- cells from Cd11b+ cells. (B) Percentage of Ccr2+Ly6c+ cells from Cd11b+ cells. (C) Percentage of Cd11b+F4/80+ cells from Cd45+ cells. (D) Percentage of Ly6g+ from Cd45+ cells. (E) Percentage of Cd3+ cells from Cd45+ cells. (F) Ly6c+ per HPF (High Power Field) immunostaining (left) and analysis of total Ly6c+ cells from Cd45+Cd11b+ cells by flow cytometry (right). Data are represented as the mean ± S.E.M. (n = 5-16 mice per group). Statistical analysis was performed by Kruskal-Wallis, one-way ANOVA or Brown-Forsythe and Welch ANOVA test followed by their respective post-hoc test. * P < 0.05 and *** P < 0.001 vs. 2 m/o; ## P < 0.01 vs. 14 m/o.
Supplementary Figure 5. Analysis of non-lymphoid inflammatory population in PBMCs from 2 m/o, 14 m/o and 14 m/o + APAP mice by flow cytometry. (A) Percentage of Cd11b^+F4/80^+ cells from Cd45^+ cells. (B) Percentage of Ly6g^+ from Cd45^+ cells. (C) Percentage of Cd3^+ cells from Cd45^+ cells. Data are represented as the mean ± S.E.M. (n = 9-14 mice per group). Statistical analysis was performed by Kruskal-Wallis or Brown-Forsythe and Welch ANOVA test followed by their respective post-hoc test. * P < 0.05 vs. 2 m/o; ** P < 0.01 vs. 14 m/o.
Supplementary Figure 6. Data from Figure 3A.
Supplementary Figure 7. Data from Figure 3E.
Supplementary Figure 8. Data from Supplementary Figure 2.